Deubiquitinating enzymes as cancer biomarkers: new therapeutic opportunities?

• Published in: BMB reports Vol. 52; no. 3; pp. 181 - 189
• Main Authors: Poondla, Naresh, Chandrasekaran, Arun Pandian, Kim, Kye-Seong, Ramakrishna, Suresh
• Format: Journal Article
• Language: Korean
• Published: 생화학분자생물학회 31.03.2019
• Subjects: Cancer; Deubiquitinating enzymes; Gene therapy; Inhibitors; Otubain protease; Ubiquitin-specific protease; Ubiquitin-specific protease; Deubiquitinating enzymes; Inhibitors; Gene therapy; Otubain protease; Cancer
• ISSN: 1976-6696; 1976-670X

Cancer remains a life-threatening disease and accounts for the major mortality rates worldwide. The practice of using biomarkers for early detection, staging, and customized therapy may increase cancer patients’ survival. Deubiquitinating enzymes (DUBs) are a family of proteases that remove ubiquitin tags from proteins of interest undergoing proteasomal degradation. DUBs play several functional roles other than deubiquitination. One of the important roles of DUBs is regulation of tumor progression. Several reports have suggested that the DUB family members were highly-elevated in various cancer cells and tissues in different stages of cancer. These findings suggest that the DUBs could be used as drug targets in cancer therapeutics. In this review, we recapitulate the role of the DUB family members, including ubiquitin-specific protease, otubain protease, and important candidates from other family members. Our aim was to better understand the connection between DUB expression profiles and cancers to allow researchers to design inhibitors or gene therapies to improve diagnosis and prognosis of cancers. [BMB Reports 2019; 52(3): 181-189]